“Novel protocol combining metronomic
Nant-paclitaxel with HER2-targeted natural killer cells (innate
immunotherapy) for HER2-positive metastatic breast cancer”
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases and
NantCell, an immuno-oncology company focused on the discovery of
innovative molecularly targeted therapeutics, announced today that
preclinical results from the company’s HER2.taNK program will
presented at the San Antonio Breast Cancer Symposium (SABCS),
December 8-12, 2015, in San Antonio, Texas.
"NantKwest is focused on bringing transformative, NK cell-based
therapies to cancer patients that are designed to dramatically
improve clinical outcomes. We will be presenting data from this
recently completed research study in collaboration with the Windber
Medical Center and NantCell at the upcoming SABCS meeting that
demonstrates the synergistic use of low dose, metronomic
Nant-paclitaxel in combination with our NK cell-based therapy,”
said Patrick Soon-Shiong, MD, Chairman and CEO of NantKwest. "The
results of this study supports the foundation for our HER2.taNK
program, as well as several additional therapeutic programs that
will transition to human clinical trials in 2016. We look forward
to sharing more specific details on our clinical trial plans in the
next few months.”
Details of the presentations are listed below and available on
the SABCS website:
Title: “Novel protocol combining metronomic
Nant-paclitaxel with HER2-targeted natural killer cells (innate
immunotherapy) for HER2-positive metastatic breast cancer”
Poster Session: Thursday, December 10, 2015, Poster
Session 2: Treatment: Immunotherapy (Clinical) (7:30 AM-9:00
AM)
Authors: Rabizadeh S, Simon B, Klingemann H, Sims D,
Weiss R, Soon-Shiong P. NantCell, Inc, Culver City, CA; NantKwest,
Inc, Culver City, CA; Windber Medical Center, Windber, PA
Conclusion
Results show that Nant-paclitaxel alone and HER2.taNK alone
significantly inhibited tumor growth. The combination of
Nant-paclitaxel + HER2.taNK led to significant tumor regressions
(p<0.05). Abstracts are available to the public online on the
SABCS website: www.sabcs.org.
About NantKwest Inc.
NantKwest (Nasdaq:NK) is a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases. NK
cells are the body’s first line of defense due to the innate
ability of NK cells to rapidly identify and destroy cells under
stress, such as cancer or virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to
grow active killer cells as a biological cancer therapy, has been
designed to induce cell death against cancer or infected cells by
three different modes of action: (1) Direct killing using activated
NK cells (aNK) that release toxic granules directly into the cell
through cell to cell contact, (2) Antibody-mediated killing using
haNKs, which are NK cells engineered to incorporate a high affinity
receptor that binds to an administered antibody, enhancing the
cancer cell killing effect of that antibody, and (3) Targeted
activated killing using taNKs, which are NK cells engineered to
incorporate chimeric antigen receptors (CARs) to target
tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of
T cell therapies including the reduction of risk of serious
"cytokine storms" reported after T cell therapy. As an
“off-the-shelf” therapy, NantKwest's NK cells do not rely on a
patient’s own often compromised immune system. In Phase 1 clinical
trials in patients with late stage cancer, NantKwest's NK cells
have been successfully administered as an outpatient infusion
therapy without any reported severe side effects, even at doses of
10 billion cells.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs that
include a Phase 2 trial for a rare form of melanoma and the planned
initiation of a clinical trial of NK cells targeted to breast
cancer, we believe NantKwest is uniquely positioned to be the
premier immunotherapy company and transform medicine by delivering
living drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care. For more information please
visit http://www.nantkwest.com and follow Dr. Soon-Shiong on
Twitter @solvehealthcare.
About NantCell
NantCell, a wholly-owned subsidiary of NantWorks, LLC, is an
immuno-oncology company focused on the discovery and development of
innovative, molecularly targeted immunotherapeutics based on the
proteomic profile of the patient's tumor, independent of the
cancer's anatomical type. Dr. Patrick Soon-Shiong, the creator of
Abraxane® and the founder of the nab® technology platform
established NantCell to develop a pipeline of human antibodies and
inhibitors of proteins which drive tumor growth and pursue the
development of Chimeric Receptor Antigen platforms for use in both
T cell and NK cell therapy. NantCell's mission is to make obsolete
the standard method of clinical trial design of "trial and error"
and replace it with a level of quantitative predictability based on
both the genomic and proteomic profile performed a priori. The
Company will tap into comprehensive “omic” analytic tools and "big
data" generated from supercomputing to develop molecularly designed
drugs in this era of genomics and proteomics and identify patients
and their tumor signature at the most granular cellular, DNA and
protein levels. Patients entering clinical trials would be
identified after a comprehensive “omic” analysis from tissue to
cell to DNA to RNA to protein to peptide to drug, and tested based
on this molecular profile to maximize clinical outcome and minimize
side effects. Through these integrated diagnostic methods, the
company is pursuing the vision of treating the biology of cancer
rather than the anatomy, and drive the immune system inherited by
all to defeat cancer. For more information please
visit www.nanthealth.com and follow Dr. Soon-Shiong on
Twitter @solvehealthcare.
About NantWorks
NantWorks, LLC, founded by renowned physician scientist and
inventor of the first human nanoparticle chemotherapeutic agent
Abraxane®, Dr. Patrick Soon-Shiong, is the umbrella organization
for the following entities: NantHealth, NantMobileHealth,
NantOmics, NantBio, NantCell, NantPharma, NantCapital and
NantCloud. Fact-based and solution-driven, each of NantWorks’
division entities operates at the nexus of innovation and
infrastructure.
The core mission of NantWorks is convergence and a systems
approach to human biology: to develop and deliver a diverse range
of technologies that accelerates innovation, broaden the scope of
scientific discovery, enhance ground-breaking research, and improve
healthcare treatment for those in need. NantWorks is building an
integrated fact-based, genomically and proteomically -informed,
personalized approach to the delivery of care and the development
of next generation diagnostics and therapeutics for life
threatening diseases such as Cancer, Infectious Diseases and
Alzheimer’s. For more information please visit
www.nantworks.com and follow Dr. Soon-Shiong on
Twitter @solvehealthcare.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151209005450/en/
NantWorksJen Hodson, 562-397-3639jhodson@nantworks.com
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024